on NFL BIOSCIENCES (EPA:ALNFL)
NFL Biosciences Restructures Scientific Committee for NFL-101 Advancement
On May 12, 2025, NFL Biosciences, a biopharmaceutical firm from Montpellier, France, announced it has restructured its Scientific Committee. This enhancement aims to support the development of NFL-101, a botanical smoking cessation therapy, expected to enter Phase 3 clinical trials. NFL-101 is recognized for its novel formulation that requires just two administrations and boasts better tolerability and efficacy than varenicline in reducing cravings.
Three renowned experts in addiction research and a leading immunologist join NFL Biosciences' committee. Harvard's Prof. Scott E. Lukas, expert in nicotine addiction, continues his collaboration. Prof. Bernard Le Foll from the University of Toronto adds his expertise in tobacco addiction. From the University of Tasmania, Prof. Stuart G. Ferguson contributes with his knowledge in smoking cessation strategies. Finally, Paris-based Prof. Eric Tartour, an immunology specialist, strengthens the team.
This strategic move highlights the company’s dedication to advancing NFL-101 towards regulatory approval, aiming for a significant breakthrough in smoking addiction treatment.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all NFL BIOSCIENCES news